Concurrent Loss of Chromosome Arm 1p and Chromosome 3 Predicts a Decreased Disease-free Survival in Uveal Melanoma Patients
Overview
Authors
Affiliations
Purpose: Uveal melanoma is a highly malignant disease with a mortality rate of 50% at 10 to 15 years. Previous studies have shown that chromosomal changes are associated with decreased survival of the patient. However, in these studies the small number of tumors analyzed did not allow robust statistical analysis. In the present study, the independent numerical changes in chromosomes 1, 3, 6, and 8 on disease-free survival (DFS) was assessed in a large series of patients with uveal melanoma.
Methods: One hundred twenty tumors from patients with uveal melanoma were analyzed for numerical changes in chromosomes 1, 3, 6, and 8, with cytogenetic analysis, fluorescent in situ hybridization, and/or comparative genomic hybridization. Data were correlated with disease outcome in univariate and multivariate analyses, by Kaplan-Meier and Cox regression analyses.
Results: At a mean follow-up time of 45 months, 42 patients had died or had metastatic disease. In the univariate analysis, loss of chromosome 3, gain of 8q, largest tumor diameter, or the presence of epithelioid cells was associated with a decreased DFS. In the multivariate analysis, the effect of monosomy 3 on survival was largely modified by changes in 1p36. Regarding all chromosomal changes, only the concurrent loss of the short arm of chromosome 1 and all of chromosome 3 was an independent prognostic parameter for disease-free survival (P < 0.001).
Conclusions: In uveal melanoma, concurrent loss of the short arm of chromosome 1 and all of chromosome 3 is an independent predictor of decreased DFS.
The role of circulating tumor DNA in melanomas of the uveal tract.
Zameer M, Jou E, Middleton M Front Immunol. 2024; 15():1509968.
PMID: 39697328 PMC: 11652350. DOI: 10.3389/fimmu.2024.1509968.
Lalonde E, Li D, Ewens K, Shields C, Ganguly A Cancers (Basel). 2024; 16(15).
PMID: 39123378 PMC: 11312132. DOI: 10.3390/cancers16152650.
Construction of oxidative phosphorylation-related prognostic risk score model in uveal melanoma.
Zhan Z, Lin K, Wang T BMC Ophthalmol. 2024; 24(1):204.
PMID: 38698303 PMC: 11067154. DOI: 10.1186/s12886-024-03441-6.
Management of Uveal Melanoma: Updated Cancer Care Alberta Clinical Practice Guideline.
Weis E, Surgeoner B, Salopek T, Cheng T, Hyrcza M, Kostaras X Curr Oncol. 2024; 31(1):24-41.
PMID: 38275828 PMC: 10814960. DOI: 10.3390/curroncol31010002.
Nguyen J, Drabarek W, Vaarwater J, Yavuzyigitoglu S, Verdijk R, Paridaens D Ophthalmol Sci. 2024; 4(2):100413.
PMID: 38187129 PMC: 10767501. DOI: 10.1016/j.xops.2023.100413.